Stock events for Tactile Systems Technology, Inc. (TCMD)
In the past six months, Tactile Systems Technology, Inc. (TCMD) stock has been impacted by several key events. In November 2025, Q3 earnings fell short of expectations, leading to a downgrade by Oppenheimer due to mixed financial results and legal uncertainties. In February 2026, strong Q4 earnings led to a stock surge, attributed to increased sales in airway clearance and lymphedema devices. Also in February 2026, Tactile Systems Technology acquired LymphaTech for $6.8 million upfront, enhancing lymphedema solutions. The company provided a bullish outlook for fiscal year 2026, forecasting sales between $357 million and $365 million, and adjusted EBITDA in the range of $49 million to $51 million. Insiders have sold more company stock than they have bought in the past three months, with sales totaling $1,583,099.00. TCMD shares have traded between $8.61 and $37.77 in the last year.
Demand Seasonality affecting Tactile Systems Technology, Inc.’s stock price
Tactile Systems Technology, Inc. experiences seasonality in demand, with reduced demand in the first quarter due to new insurance years and unmet out-of-pocket obligations. Conversely, higher revenue is generally seen in the third and fourth quarters as patients meet deductibles and utilize flexible spending accounts. This seasonality specifically applies to patient purchases and rentals of their products.
Overview of Tactile Systems Technology, Inc.’s business
Tactile Systems Technology, Inc., also known as Tactile Medical, is a medical technology company based in Minneapolis, Minnesota. They specialize in at-home medical devices for chronic diseases in the United States, operating within the Healthcare sector, specifically the Medical Equipment and Medical Devices industry. Their major products include the Flexitouch Plus system for lymphedema and related conditions, the Entre Plus System for lymphedema and chronic wounds, Nimbl for lower extremity lymphedema, AffloVest for retained pulmonary secretions, and Kylee, a mobile application for lymphedema patients. The company secures prescription referrals and manages insurance reimbursement to deliver devices directly to patients.
TCMD’s Geographic footprint
Tactile Systems Technology, Inc. currently operates and sells exclusively within the United States, with plans for future international expansion.
TCMD Corporate Image Assessment
In the past year, Tactile Systems Technology has generally maintained a positive brand reputation among analysts, receiving a consensus rating of "Moderate Buy" from seven analysts. The company's MarketBeat MarketRank™ score indicates it performs better than 87% of companies evaluated in the medical sector. However, an adverse event report was filed with the FDA in January 2026 concerning a Flexitouch Plus system, where a patient reported a possible bone infection due to a non-healing pressure sore.
Ownership
Tactile Systems Technology, Inc. has significant institutional ownership. As of early March 2026, 293 institutional owners and shareholders held a total of 23,180,993 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Morgan Stanley, Dimensional Fund Advisors Lp, Cadian Capital Management, Lp, Acadian Asset Management Llc, Paradigm Capital Management Inc/ny, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Federated Hermes, Inc., and Arrowstreet Capital, Limited Partnership. Institutions hold 83.43% of the stock, while insiders hold 2.50%.
